Top Markets
Coin of the day
Chinook Therapeutics, Inc. Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.

KDNY
주식 순위 #7143
Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical... Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. The firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.
주가
$40.39
마지막 동기화: 2023-08-18
시가총액
$1.70B
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Chinook Therapeutics, Inc. (KDNY)

카테고리

Chinook Therapeutics, Inc. (KDNY)의 배당 이력
Chinook Therapeutics, Inc. (주식 심볼: KDNY)은 총 0회의 배당금을 지급했습니다.
모든 배당금의 합계 (주식 분할 반영): 0.00
배당 수익률 (TTM): 0
Chinook Therapeutics, Inc. (KDNY)의 2026부터 2026까지 배당 지급 내역
연간 배당 지급
연도 배당금 (주식 분할 조정됨) 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
모든 배당 지급 목록
연도 배당금 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 배당 지급
회사 배당 지급 횟수 국가
0.00%
US
0.00%
NL
64.00%
AU
0.00%
US
0.00%
CH